# First Tracks Biotherapeutics Inc. (TRAX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $46.34, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). First Tracks Biotherapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 9.7×**. The shares trade at 9.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -7.6%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -41.8%**. Return on equity is negative because earnings are negative.

## Financial health
- **Debt to equity: 0.04**. Debt is 0.04 times equity: a conservative balance sheet.
- **Current ratio: 10.78** (quick 10.78). Current assets cover the next year's liabilities 10.78 times.

## Dividends
- **Dividend: none**. First Tracks Biotherapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover First Tracks Biotherapeutics Inc.; the consensus is strong_buy, with an average price target of $74.17 (+60% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -7.2%** (214.8% above the low). Trading 7% below its 52-week high.
- **RSI (14-day): 66**. An RSI of 66 is neutral.
- **Beta (1 yr): 2.59** (volatility 125%). Beta of 2.59 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TRAX · Page: https://foliofundamentals.com/stocks/trax

Not investment advice.